RARRES2 and COVID-19: It appears that if tocilizumab can reduce circulating chemerin, we can think of this as a mechanism to treat cytokine storms and reduce the risk of thrombosis in patients with COVID-19, although this mechanism certainly needs further investigation to be proved.